Paxlovid Boceprevir Intermediate CAS 565456-77-1 Assay ≥99.0%
Mea Kūʻai Kūʻai PF-07321332 Paxlovid E pili ana i waena me ke kūlana kiʻekiʻe.
L-tert-Leucine (H-Tle-OH) CAS 20859-02-3
Caronic Anhydride CAS 67911-21-1
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride 565456-77-1
Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane CAS 943516-54-9
Inoa Kimia | (1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride |
Nā huaʻōlelo like | Methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate Hydrochloride |
Helu CAS | 565456-77-1 |
Helu CAT | RF-PI318 |
Kūlana Kūʻai | Ma ka waihona, hoʻonui ʻia a hiki i nā tona |
ʻĀpana Molekala | C9H15NO2.ClH |
Kaumaha Molecular | 205.683 |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Keʻokeʻo a hiki i ka pauda keʻokeʻo |
ʻIkepili A | IR: E like me ka mea kuhikuhi |
ʻIkepili B | Manawa Hoʻopaʻa: E like me ka mea kuhikuhi |
Enantiomer | ≤0.15% |
Ka haumia pili (na HPLC) | |
He haumia ʻike ʻole | ≤0.20% |
Huina paumaele | ≤1.0% |
Wai | ≤0.50% |
Koena ma ka Ignition | ≤0.10% |
Nā Metala Kaumaha | ≤20ppm |
Hoʻāʻo | ≥99.0% |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | Kūwaena o PF-07321332 Paxlovid (CAS 2628280-40-8) a me Boceprevir (CAS 394730-60-0) |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride (CAS 565456-77-1) he azabicyclohexane derivative i hoʻohana ʻia i ka hoʻomākaukau ʻana i ka hepatitis C. mea hoʻomaʻi (HCV) NS3 serine protease inhibitor.ʻO ia ka waena o PF-07321332 Paxlovid (CAS 2628280-40-8) a me Boceprevir (CAS 394730-60-0).ʻO PF-07321332 kahi mea hoʻomake a me ka waha i ka SARS-CoV 3C-like protease (3CLPRO) inhibitor.Kuhi ʻia ʻo PF-07321332 i ka maʻi SARS-CoV-2 a hiki ke hoʻohana ʻia no COVID-19 reseacrch.ʻO Boceprevir (INN, inoa kalepa ʻo Victrelis) he mea hoʻopaneʻe protease i hoʻohana ʻia ma ke ʻano he lapaʻau no ka maʻi hepatitis C genotype 1. Hoʻopaʻa ʻo ia i ka HCV nonstructural 3 NS3 (HCV) kahua ikaika.Ke kūkulu ʻia nei e Schering-Plough, akā ke kūkulu ʻia nei e Merck mai ka wā i loaʻa ai ʻo Schering i ka makahiki 2009. Ua ʻae ʻia e ka FDA ma Mei 13, 2011.